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The psychedelic drug class includes mescaline, psilocybin, dimethyltryptamine (DMT),         
and D-lysergic acid diethylamide (LSD). Psychedelics have been known to have           
‘mind-manifesting’ or ‘soul-revealing’ effects. It is likely that these drugs have been used in              
prehistoric times, particularly for church ceremonies, healing practices, and spiritual ceremonies.           
By the end of the 1960s, the use of psychedelics shifted and it was being used in medical trials to                    
see if it could help those with non-psychotic and psychotic mental health issues. Trials including               
patients with depression, anxiety, obsessive, and addictive disorders showed promise for           
psychedelics having therapeutic potential and a low risk of toxicity. However, research came to a               
halt when psychedelics were classified as Schedule I drugs. This schedule means that it has no                
accepted medical use and the maximum potential for harm and dependence​1​. Although this may              
be changing soon since scientists are researching the use of psychedelics to treat various mental               
health illnesses​2​.  
According to Thomas Anderson, et al. (1970)​3​, microdosing psychedelics in comparison           
to full-dose therapies are showing positive effects on those with depression and anxiety.             
Microdosing refers to the practice of consuming very low doses of psychedelic substances such              
as LSD or psilocybin rather than taking a full dose of these drugs. While full-dose therapies may                 
lead to perception-distorting properties, microdosing therapies can lead to clinical benefits. In            
this observational study, the control group did not partake in microdosing and were found to               
have fewer changes in dysfunctional attitudes, negative emotionality, wisdom, open-mindedness,          
and creativity. Those participants that did partake in microdosing were found to have lower              
scores on dysfunctional attitudes and negative emotionality and higher on open-mindedness and            
creativity. Negative emotionality includes feelings of anxiety, depression, or emotional volatility.           
These negative emotions are a predictor of mental and physical health problems​3​. This displays a               
significant difference between those who microdose psychedelics and the non-microdosing          
control group.  
In another study conducted at John Hopkins University, 51 cancer patients underwent a             
randomized, double-blind, crossover trial to investigate the differences in high dose psilocybin            
versus low dose psilocybin. Over five weeks, patients were administered a very low, placebo-like              
dose of psilocybin (1 or 3 mg) or a high dose of psilocybin (22 or 30 mg). After five weeks and a                      
six-month follow-up, those who received a high dose of psilocybin showed better outcomes in              
anxiety and depression than those who received the placebo. The study also measured death              
acceptance, to which those on the high dose psilocybin scored higher as well. As shown in this                 
study, it is evident that the psilocybin dose helped with anxiety and depression in cancer patients                
with a life-threatening diagnosis​4​.  
A similar study conducted at New York University used niacin as the control rather than               
the low-dose psilocybin. In this randomized double-blind control trial, 29 patients with            
cancer-related anxiety and depression were either placed on niacin or single-dose psilocybin in a              
span of seven weeks. Upon the six and a half-week mark, those that received the psilocybin in                 
this study experienced a decrease in their anxiety and depression, an increased quality of life, and                
an improved mood towards death. As in the previous studies, this study displays that the use of                 
psilocybin under the supervision of professionals can reduce anxiety and depression​5​.  
According to Peter Gasser, et. al, (2014)​6 LSD-assisted psychotherapy has positive and            
stable outcomes on those with anxiety relating to life-threatening illnesses. 12 patients with             
anxiety associated with a life-threatening illness were a part of this double-blind, randomized,             
active placebo-control study. The patients either received 200 μg of LSD (freebase) or 20 μg of                
LSD (a low dose comparator). After a two-month follow-up, it was found that the patients that                
received the 200 μg of LSD had a significant decrease in anxiety. This reduction was sustained                
for 12 months. Thus, it was shown that with medically supervised doses of LSD it is possible to                  
reduce anxiety​6​.  
In 1960, two psychologists at Harvard, Timothy Leary and Richard Alpert, started The             
Harvard Psilocybin Project. This project aimed to show the difference between the human mind              
while on psychedelics. However, in 1963, Harvard fired Leary and Alpert and shut down their               
research project because they were administering LSD to their students​2,7​. Fortunately, this            
outcome is no longer the case for researchers today. As stated previously, scientists are now               
exploring the roles of hallucinogens on treatment-resistant depression, post-traumatic stress          
disorder, cancer-related anxiety, addictions, and perhaps even anorexia​2​. While this paper only            
includes depression and anxiety, both cancer and non-cancer related, it is evident that             
psychedelics have the chance to be a revolutionary drug in pharmacy and medicine alike.              
Although studies have begun to show promise in the use of psychedelics for mental health               
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